[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-001", "question": "A 16-year-old female presents with episodes of muscle weakness and palpitations. Physical exam reveals low-set ears, micrognathia, and clinodactyly. ECG demonstrates frequent PVCs, a QTc of 490 ms, and prominent U waves. Genetic testing confirms a loss-of-function mutation in KCNJ2. She continues to have frequent non-sustained ventricular tachycardia despite beta-blocker therapy. What is the most appropriate pharmacologic management for her arrhythmia?", "options": ["Option A: Nadolol", "Option B: Amiodarone", "Option C: Flecainide", "Option D: Mexiletine", "Option E: Verapamil"], "answer": "C", "answer_index": 2, "explanation": "This patient has Andersen-Tawil Syndrome (LQT7), characterized by the triad of periodic paralysis, dysmorphic features, and QT/U wave abnormalities. Unlike other Long QT Syndromes where sodium channel blockers are often contraindicated, Flecainide is uniquely effective in suppressing the ventricular arrhythmias associated with KCNJ2 mutations.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include dysmorphic features (low-set ears, micrognathia, clinodactyly), episodic muscle weakness, palpitations, ECG with PVCs, prolonged QTc (490 ms), prominent U waves, KCNJ2 loss-of-function mutation, and non-sustained VT refractory to beta-blockers. These point to Andersen-Tawil Syndrome (ATS; LQT7), where ventricular arrhythmias persist despite beta-blockade. The question asks for the most appropriate pharmacologic management. Flecainide (C) is the best choice, as it suppresses arrhythmias in KCNJ2-related ATS by modulating sodium channels, per established literature. Alternatives: Nadolol (A) is a beta-blocker, ineffective here; Amiodarone (B) is broad but not first-line for ATS; Mexiletine (D) is another sodium blocker but less evidence-specific; Verapamil (E) is unsuitable for VT. No main logical issues; stem allows discrimination without contradictions or underspecification. No medical accuracy issues; aligns with current guidelines on ATS management, where flecainide is recommended for refractory cases. Minimal fix: None needed, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include dysmorphic features (low-set ears, micrognathia, clinodactyly), episodic muscle weakness, palpitations, ECG with PVCs, prolonged QTc (490 ms), prominent U waves, KCNJ2 loss-of-function mutation, and non-sustained VT refractory to beta-blockers. These point to Andersen-Tawil Syndrome (ATS; LQT7), where ventricular arrhythmias persist despite beta-blockade. The question asks for the most appropriate pharmacologic management. Flecainide (C) is the best choice, as it suppresses arrhythmias in KCNJ2-related ATS by modulating sodium channels, per established literature. Alternatives: Nadolol (A) is a beta-blocker, ineffective here; Amiodarone (B) is broad but not first-line for ATS; Mexiletine (D) is another sodium blocker but less evidence-specific; Verapamil (E) is unsuitable for VT. No main logical issues; stem allows discrimination without contradictions or underspecification. No medical accuracy issues; aligns with current guidelines on ATS management, where flecainide is recommended for refractory cases. Minimal fix: None needed, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-002", "question": "A 55-year-old man presents with bone pain and exophthalmos. CT imaging reveals perinephric infiltration with a 'hairy kidney' appearance and osteosclerotic lesions in the distal femur. Biopsy of the retroperitoneal tissue shows infiltration by foamy histiocytes that are CD68+ and CD1a-. Molecular testing reveals a BRAF V600E mutation. Which therapeutic agent is most indicated?", "options": ["Option A: Rituximab", "Option B: High-dose Prednisone", "Option C: Vemurafenib", "Option D: Methotrexate", "Option E: Infliximab"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation (hairy kidney, osteosclerosis, exophthalmos) and pathology (CD68+, CD1a- foamy histiocytes) are diagnostic of Erdheim-Chester Disease (ECD), a non-Langerhans cell histiocytosis. Over 50% of cases carry the BRAF V600E mutation. Targeted therapy with a BRAF inhibitor (Vemurafenib) is the treatment of choice for BRAF-positive ECD, superior to empiric immunosuppression.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: 55-year-old man with bone pain, exophthalmos, CT showing perinephric 'hairy kidney' infiltration and distal femoral osteosclerotic lesions, retroperitoneal biopsy with CD68+ CD1a- foamy histiocytes, and BRAF V600E mutation. These clues diagnostically point to Erdheim-Chester Disease (ECD), a non-Langerhans histiocytosis with characteristic multisystem involvement and frequent BRAF mutations, making targeted BRAF inhibition the most indicated therapy.\\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify ECD and prioritize BRAF-targeted therapy over nonspecific immunosuppression, supporting a single best answer without contradictions or underspecification.\\nMain medical accuracy issue(s), if any: None; the presentation aligns with established ECD criteria (e.g., per WHO classification), and Vemurafenib as a BRAF inhibitor is consistent with current guidelines (e.g., NCCN and expert consensus) for BRAF V600E-positive ECD, representing first-line targeted therapy superior to alternatives like steroids or methotrexate in mutated cases.\\nMinimal fix: N/A; the item is already unambiguous and accurate, though optionally adding 'BRAF inhibitor' in the rationale could enhance clarity without altering content.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: 55-year-old man with bone pain, exophthalmos, CT showing perinephric 'hairy kidney' infiltration and distal femoral osteosclerotic lesions, retroperitoneal biopsy with CD68+ CD1a- foamy histiocytes, and BRAF V600E mutation. These clues diagnostically point to Erdheim-Chester Disease (ECD), a non-Langerhans histiocytosis with characteristic multisystem involvement and frequent BRAF mutations, making targeted BRAF inhibition the most indicated therapy.\nMain logical issue(s), if any: None; the stem provides sufficient discriminating details to identify ECD and prioritize BRAF-targeted therapy over nonspecific immunosuppression, supporting a single best answer without contradictions or underspecification.\nMain medical accuracy issue(s), if any: None; the presentation aligns with established ECD criteria (e.g., per WHO classification), and Vemurafenib as a BRAF inhibitor is consistent with current guidelines (e.g., NCCN and expert consensus) for BRAF V600E-positive ECD, representing first-line targeted therapy superior to alternatives like steroids or methotrexate in mutated cases.\nMinimal fix: N/A; the item is already unambiguous and accurate, though optionally adding 'BRAF inhibitor' in the rationale could enhance clarity without altering content.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-003", "question": "A 32-year-old G1P0 woman at 35 weeks gestation presents with nausea, vomiting, and jaundice. Labs show AST 300 U/L, ALT 350 U/L, Platelets 80,000/mm3, Glucose 45 mg/dL, and INR 2.5. A diagnosis of Acute Fatty Liver of Pregnancy (AFLP) is made, and the infant is delivered urgently. To prevent sudden death in the neonate, which specific screening test should be prioritized?", "options": ["Option A: Serum ammonia and lactate", "Option B: Plasma acylcarnitine profile", "Option C: Galactose-1-phosphate uridyltransferase", "Option D: Very long-chain fatty acids (VLCFA)", "Option E: Hemoglobin electrophoresis"], "answer": "B", "answer_index": 1, "explanation": "Maternal AFLP is strongly associated with fetal Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency. Fetal fatty acid oxidation defects cause accumulation of metabolites that cross the placenta and overwhelm the maternal liver. The neonate is at high risk for hypoketotic hypoglycemia and sudden death; an acylcarnitine profile is diagnostic.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the maternal diagnosis of Acute Fatty Liver of Pregnancy (AFLP) at 35 weeks gestation, with symptoms of nausea, vomiting, jaundice, and labs showing elevated AST/ALT, thrombocytopenia, hypoglycemia, and coagulopathy, leading to urgent delivery. These clues strongly imply the need to screen the neonate for associated fatty acid oxidation disorders, particularly LCHAD deficiency, to prevent sudden death from hypoketotic hypoglycemia. The keyed answer B (plasma acylcarnitine profile) fits perfectly as it is the diagnostic test for such defects, based on the known pathophysiology where fetal metabolites affect the maternal liver. Alternatives are inferior: A (serum ammonia and lactate) targets urea cycle disorders, not FAOD; C (galactose-1-phosphate uridyltransferase) screens for galactosemia; D (VLCFA) assesses peroxisomal disorders; E (hemoglobin electrophoresis) detects hemoglobinopathies, none directly linked to AFLP. No main logical issues; the stem is sufficient and consistent, allowing discrimination of a single best answer without contradictions or underspecification. No main medical accuracy issues; this aligns with current guidelines on AFLP's association with fetal LCHAD deficiency and the role of acylcarnitine profiling in neonatal screening to avert metabolic crises. Minimal fix: None required, as the item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include the maternal diagnosis of Acute Fatty Liver of Pregnancy (AFLP) at 35 weeks gestation, with symptoms of nausea, vomiting, jaundice, and labs showing elevated AST/ALT, thrombocytopenia, hypoglycemia, and coagulopathy, leading to urgent delivery. These clues strongly imply the need to screen the neonate for associated fatty acid oxidation disorders, particularly LCHAD deficiency, to prevent sudden death from hypoketotic hypoglycemia. The keyed answer B (plasma acylcarnitine profile) fits perfectly as it is the diagnostic test for such defects, based on the known pathophysiology where fetal metabolites affect the maternal liver. Alternatives are inferior: A (serum ammonia and lactate) targets urea cycle disorders, not FAOD; C (galactose-1-phosphate uridyltransferase) screens for galactosemia; D (VLCFA) assesses peroxisomal disorders; E (hemoglobin electrophoresis) detects hemoglobinopathies, none directly linked to AFLP. No main logical issues; the stem is sufficient and consistent, allowing discrimination of a single best answer without contradictions or underspecification. No main medical accuracy issues; this aligns with current guidelines on AFLP's association with fetal LCHAD deficiency and the role of acylcarnitine profiling in neonatal screening to avert metabolic crises. Minimal fix: None required, as the item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-004", "question": "A 24-year-old male with HIV and known G6PD deficiency develops cyanosis and dyspnea after receiving dapsone. SpO2 is 85% and arterial blood is chocolate-colored. Methemoglobin level is 25%. He is inadvertently treated with methylene blue, after which his condition deteriorates with evidence of acute hemolysis and worsening hypoxia. What is the most appropriate next step in management?", "options": ["Option A: Repeat Methylene Blue dose", "Option B: High-dose Ascorbic Acid (Vitamin C)", "Option C: Exchange transfusion", "Option D: Hyperbaric oxygen therapy", "Option E: Hydroxocobalamin"], "answer": "C", "answer_index": 2, "explanation": "Methylene blue requires NADPH (generated via the G6PD pathway) to reduce methemoglobin. In G6PD deficiency, it is ineffective and can induce severe hemolysis (as seen here). Ascorbic acid is too slow for acute severe toxicity. Exchange transfusion is the definitive rescue therapy to rapidly remove the methemoglobin and the offending agent.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include G6PD deficiency, methemoglobinemia (25% MetHb, chocolate-colored blood, SpO2 85%, cyanosis/dyspnea) induced by dapsone, and deterioration with hemolysis after methylene blue, indicating need for rescue therapy beyond standard reduction. The clinical problem asks for the next management step in severe, refractory methemoglobinemia with hemolysis in G6PD deficiency. Discriminating findings: Ineffective/harmful methylene blue due to NADPH dependence, acute worsening hypoxia/hemolysis. Most likely mechanism: Oxidant stress from dapsone and methylene blue in G6PD-deficient patient. Keyed answer C (exchange transfusion) fits as definitive removal of MetHb and toxins in severe cases unresponsive to other therapies. Alternatives: A worsens hemolysis; B (ascorbic acid) is slow-acting for acute severity; D (hyperbaric oxygen) addresses hypoxia supportively but not MetHb directly; E (hydroxocobalamin) is for cyanide toxicity, not MetHb. No main logical issues; item supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines (e.g., exchange transfusion for severe MetHb in G6PD deficiency per toxicology standards). Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include G6PD deficiency, methemoglobinemia (25% MetHb, chocolate-colored blood, SpO2 85%, cyanosis/dyspnea) induced by dapsone, and deterioration with hemolysis after methylene blue, indicating need for rescue therapy beyond standard reduction. The clinical problem asks for the next management step in severe, refractory methemoglobinemia with hemolysis in G6PD deficiency. Discriminating findings: Ineffective/harmful methylene blue due to NADPH dependence, acute worsening hypoxia/hemolysis. Most likely mechanism: Oxidant stress from dapsone and methylene blue in G6PD-deficient patient. Keyed answer C (exchange transfusion) fits as definitive removal of MetHb and toxins in severe cases unresponsive to other therapies. Alternatives: A worsens hemolysis; B (ascorbic acid) is slow-acting for acute severity; D (hyperbaric oxygen) addresses hypoxia supportively but not MetHb directly; E (hydroxocobalamin) is for cyanide toxicity, not MetHb. No main logical issues; item supports unique best answer without contradictions or underspecification. No main medical accuracy issues; aligns with guidelines (e.g., exchange transfusion for severe MetHb in G6PD deficiency per toxicology standards). Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-005", "question": "A 3-month-old male presents with generalized erythroderma, lymphadenopathy, hepatosplenomegaly, and chronic diarrhea. CBC reveals eosinophilia and lymphocytosis. Immunophenotyping shows an absence of B cells, but elevated numbers of oligoclonal, activated T cells. Which genetic defect is most consistent with this presentation?", "options": ["Option A: BTK mutation", "Option B: Hypomorphic RAG1/RAG2 mutation", "Option C: CD40 Ligand mutation", "Option D: STAT3 mutation", "Option E: WAS gene mutation"], "answer": "B", "answer_index": 1, "explanation": "This is Omenn Syndrome, a form of 'leaky' Severe Combined Immunodeficiency (SCID). It is caused by hypomorphic mutations in RAG1 or RAG2 that allow for partial V(D)J recombination. This results in the absence of B cells but the development of a restricted, autoreactive T-cell repertoire that infiltrates tissues (erythroderma, hepatosplenomegaly) and causes high IgE/eosinophilia.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include generalized erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absence of B cells, and elevated oligoclonal activated T cells, collectively pointing to Omenn Syndrome, a leaky SCID variant. These findings discriminate toward hypomorphic RAG1/RAG2 mutations (B), as they allow partial V(D)J recombination leading to autoreactive T-cell expansion and B-cell absence, explaining the autoimmune-like infiltrative symptoms and immunophenotype. Alternatives are inferior: A (BTK) causes B-cell deficiency without T-cell issues or erythroderma; C (CD40L) leads to hyper-IgM with normal T-cell counts; D (STAT3) involves hyper-IgE with recurrent infections but preserved B cells; E (WAS) features thrombocytopenia and eczema but not necessarily absent B cells or oligoclonal T cells. No main logical issues; the stem is internally consistent, supports a single best answer without contradictions or underspecification, and options allow clear discrimination. No main medical accuracy issues; the presentation and rationale align with current immunology consensus on Omenn Syndrome etiology per major guidelines (e.g., IUIS classification), with precise pathophysiology. Minimal fix: None required; item is already unambiguous and accurate, though adding 'elevated IgE' to stem could enhance realism without altering defensibility.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include generalized erythroderma, lymphadenopathy, hepatosplenomegaly, chronic diarrhea, eosinophilia, lymphocytosis, absence of B cells, and elevated oligoclonal activated T cells, collectively pointing to Omenn Syndrome, a leaky SCID variant. These findings discriminate toward hypomorphic RAG1/RAG2 mutations (B), as they allow partial V(D)J recombination leading to autoreactive T-cell expansion and B-cell absence, explaining the autoimmune-like infiltrative symptoms and immunophenotype. Alternatives are inferior: A (BTK) causes B-cell deficiency without T-cell issues or erythroderma; C (CD40L) leads to hyper-IgM with normal T-cell counts; D (STAT3) involves hyper-IgE with recurrent infections but preserved B cells; E (WAS) features thrombocytopenia and eczema but not necessarily absent B cells or oligoclonal T cells. No main logical issues; the stem is internally consistent, supports a single best answer without contradictions or underspecification, and options allow clear discrimination. No main medical accuracy issues; the presentation and rationale align with current immunology consensus on Omenn Syndrome etiology per major guidelines (e.g., IUIS classification), with precise pathophysiology. Minimal fix: None required; item is already unambiguous and accurate, though adding 'elevated IgE' to stem could enhance realism without altering defensibility.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-006", "question": "A 4-month-old infant presents with failure to thrive and diaphoresis during feeding. ECG reveals deep Q waves in leads I, aVL, and V5-V6. Echocardiography demonstrates a dilated left ventricle. During color Doppler interrogation of the coronary arteries, which flow pattern confirms the diagnosis of Anomalous Left Coronary Artery from the Pulmonary Artery (ALCAPA)?", "options": ["Option A: Diastolic flow from the aorta into the left coronary artery", "Option B: Systolic flow from the pulmonary artery into the left coronary artery", "Option C: Retrograde flow from the left coronary artery into the pulmonary artery", "Option D: Continuous flow from the aorta to the pulmonary artery", "Option E: Turbulent high-velocity flow at the left coronary ostium"], "answer": "C", "answer_index": 2, "explanation": "In the infant/adult type of ALCAPA, pulmonary vascular resistance drops, causing flow reversal. Blood flows from the aorta to the Right Coronary Artery, through collaterals to the Left Coronary Artery, and then retrograde into the low-pressure Pulmonary Artery (coronary steal). The hallmark is retrograde flow into the PA.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 4-month-old with failure to thrive, diaphoresis during feeding, ECG deep Q waves in I, aVL, V5-V6 indicating lateral infarction, and echocardiography showing dilated left ventricle, all classic for ALCAPA causing myocardial ischemia via coronary steal. These drive a unique best answer: retrograde flow from left coronary artery (LCA) into pulmonary artery (PA) on color Doppler, confirming the diagnosis. Main logical issues: none; stem is sufficient, consistent, and discriminates options without contradictions or underspecification, supporting C as singular best. Alternatives: A describes normal LCA flow; B implies antegrade from PA, opposite of ALCAPA reversal; D suggests shunt like PDA; E indicates possible stenosis, not specific to ALCAPA. Main medical accuracy issues: none; aligns with standard pathophysiology of ALCAPA where post-neonatal pulmonary vascular resistance drop leads to retrograde LCA flow into low-pressure PA, stealing from myocardium. This is consistent with current guidelines and board-level knowledge. Minimal fix: none required, as item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues include 4-month-old with failure to thrive, diaphoresis during feeding, ECG deep Q waves in I, aVL, V5-V6 indicating lateral infarction, and echocardiography showing dilated left ventricle, all classic for ALCAPA causing myocardial ischemia via coronary steal. These drive a unique best answer: retrograde flow from left coronary artery (LCA) into pulmonary artery (PA) on color Doppler, confirming the diagnosis. Main logical issues: none; stem is sufficient, consistent, and discriminates options without contradictions or underspecification, supporting C as singular best. Alternatives: A describes normal LCA flow; B implies antegrade from PA, opposite of ALCAPA reversal; D suggests shunt like PDA; E indicates possible stenosis, not specific to ALCAPA. Main medical accuracy issues: none; aligns with standard pathophysiology of ALCAPA where post-neonatal pulmonary vascular resistance drop leads to retrograde LCA flow into low-pressure PA, stealing from myocardium. This is consistent with current guidelines and board-level knowledge. Minimal fix: none required, as item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-007", "question": "A 60-year-old male presents with nephrotic syndrome. Labs show low serum C3 and normal C4. Kidney biopsy reveals C3-dominant staining on immunofluorescence and a membranoproliferative pattern on light microscopy. Serum protein electrophoresis is negative, but serum free light chain assay shows a kappa:lambda ratio of 5.0. What is the most appropriate treatment to preserve renal function?", "options": ["Option A: Eculizumab", "Option B: Mycophenolate Mofetil", "Option C: Clone-directed chemotherapy (e.g., Bortezomib-based)", "Option D: High-dose steroids alone", "Option E: Plasma exchange"], "answer": "C", "answer_index": 2, "explanation": "This patient has C3 Glomerulopathy (C3G) secondary to a Monoclonal Gammopathy of Renal Significance (MGRS). The monoclonal protein acts as an autoantibody (e.g., C3 nephritic factor) driving complement activation. The standard of care is to treat the underlying clone (plasma cell directed therapy) rather than non-specific immunosuppression or complement inhibition alone.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Nephrotic syndrome in 60-year-old male, low serum C3 with normal C4, C3-dominant immunofluorescence and membranoproliferative pattern on biopsy, negative serum protein electrophoresis but elevated kappa:lambda ratio of 5.0, pointing to C3 glomerulopathy (C3G) secondary to monoclonal gammopathy of renal significance (MGRS). These findings imply a monoclonal protein driving complement dysregulation, making clone-directed therapy the best approach to preserve renal function. Main logical issue(s): None; stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., KDIGO) recommending treatment of underlying clone in MGRS-associated C3G, rather than nonspecific immunosuppression or complement inhibition. The rationale correctly identifies the monoclonal protein as an autoantibody-like driver (e.g., C3 nephritic factor). Best-answer defensibility: The question asks for the most appropriate treatment to preserve renal function in suspected MGRS-C3G. Key findings include complement profile and biopsy consistent with C3G, plus light chain abnormality suggesting paraprotein involvement. Keyed answer C fits as it targets the underlying plasma cell clone. Alternatives: A (eculizumab) inhibits complement but doesn't address clone; B (mycophenolate) is nonspecific; D (steroids) insufficient alone; E (plasma exchange) removes proteins but not curative. Minimal fix: Not needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Nephrotic syndrome in 60-year-old male, low serum C3 with normal C4, C3-dominant immunofluorescence and membranoproliferative pattern on biopsy, negative serum protein electrophoresis but elevated kappa:lambda ratio of 5.0, pointing to C3 glomerulopathy (C3G) secondary to monoclonal gammopathy of renal significance (MGRS). These findings imply a monoclonal protein driving complement dysregulation, making clone-directed therapy the best approach to preserve renal function. Main logical issue(s): None; stem provides sufficient discriminating details for a single best answer without contradictions or underspecification. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., KDIGO) recommending treatment of underlying clone in MGRS-associated C3G, rather than nonspecific immunosuppression or complement inhibition. The rationale correctly identifies the monoclonal protein as an autoantibody-like driver (e.g., C3 nephritic factor). Best-answer defensibility: The question asks for the most appropriate treatment to preserve renal function in suspected MGRS-C3G. Key findings include complement profile and biopsy consistent with C3G, plus light chain abnormality suggesting paraprotein involvement. Keyed answer C fits as it targets the underlying plasma cell clone. Alternatives: A (eculizumab) inhibits complement but doesn't address clone; B (mycophenolate) is nonspecific; D (steroids) insufficient alone; E (plasma exchange) removes proteins but not curative. Minimal fix: Not needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-008", "question": "A patient with severe ARDS is ventilated in Assist-Control Volume Control mode. He is deeply sedated but not paralyzed. Ventilator graphics display a time-triggered mandatory breath, followed immediately by a drop in esophageal pressure (diaphragmatic contraction) occurring during the inspiratory phase, which triggers a second breath during exhalation (breath stacking). This phenomenon is best described as:", "options": ["Option A: Double triggering due to flow starvation", "Option B: Reverse triggering", "Option C: Ineffective triggering", "Option D: Premature cycling", "Option E: Auto-triggering"], "answer": "B", "answer_index": 1, "explanation": "Reverse triggering is a form of patient-ventilator dyssynchrony where the passive insufflation from the ventilator mechanically stretches the diaphragm, reflexively inducing a patient respiratory effort (entrainment). If this induced effort is strong enough, it can trigger a second breath (breath stacking). It is distinct from double triggering caused by high patient drive.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues that drive a unique best answer: Time-triggered mandatory breath followed by esophageal pressure drop (diaphragmatic contraction) during inspiratory phase, triggering a second breath during exhalation (breath stacking) in a sedated, non-paralyzed ARDS patient on Assist-Control Volume Control. These clues point to ventilator-induced diaphragmatic effort causing breath stacking, aligning with reverse triggering.\\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as the unique best answer.\\nMain medical accuracy issue(s), if any: None; the description of reverse triggering matches current critical care consensus (e.g., ATS/ESICM guidelines on mechanical ventilation dyssynchrony), distinguishing it from double triggering (patient-driven) and other dyssynchronies like ineffective triggering (failed patient effort) or auto-triggering (artifactual). The item's teaching point on entrainment in ARDS is precise and realistic.\\nMinimal fix: No fix needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues that drive a unique best answer: Time-triggered mandatory breath followed by esophageal pressure drop (diaphragmatic contraction) during inspiratory phase, triggering a second breath during exhalation (breath stacking) in a sedated, non-paralyzed ARDS patient on Assist-Control Volume Control. These clues point to ventilator-induced diaphragmatic effort causing breath stacking, aligning with reverse triggering.\nMain logical issue(s), if any: None; the stem provides sufficient details to discriminate options without contradictions or underspecification, supporting B as the unique best answer.\nMain medical accuracy issue(s), if any: None; the description of reverse triggering matches current critical care consensus (e.g., ATS/ESICM guidelines on mechanical ventilation dyssynchrony), distinguishing it from double triggering (patient-driven) and other dyssynchronies like ineffective triggering (failed patient effort) or auto-triggering (artifactual). The item's teaching point on entrainment in ARDS is precise and realistic.\nMinimal fix: No fix needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-009", "question": "A 28-year-old G2P2 woman presents 3 months postpartum with extensive ecchymoses and bleeding from a minor cut. Coagulation studies show aPTT 78s and PT 12s. A mixing study fails to correct the aPTT. Factor VIII activity is <1%. Which agent is the most appropriate first-line therapy for acute bleeding control?", "options": ["Option A: Desmopressin (DDAVP)", "Option B: Cryoprecipitate", "Option C: Recombinant Human Factor VIII", "Option D: Recombinant Porcine Factor VIII", "Option E: High-dose Prednisone"], "answer": "D", "answer_index": 3, "explanation": "This is acquired hemophilia A (postpartum), caused by an inhibitor (autoantibody) to Factor VIII. Human Factor VIII (and Cryoprecipitate) will be neutralized by the inhibitor and is ineffective. First-line hemostatic agents are bypassing agents (rFVIIa or FEIBA) or Recombinant Porcine Factor VIII (which has low cross-reactivity with human anti-FVIII antibodies). Prednisone treats the clone but does not stop acute bleeding.", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old G2P2 woman 3 months postpartum with ecchymoses and bleeding from minor cut; aPTT 78s (prolonged), PT 12s (normal); mixing study fails to correct aPTT; Factor VIII activity <1%. These indicate acquired hemophilia A due to postpartum anti-Factor VIII inhibitor, requiring bypassing therapy for acute bleeding control. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting D as unique best (recombinant porcine Factor VIII has low cross-reactivity with human inhibitors). Alternatives inferior: A (Desmopressin) stimulates endogenous FVIII release, ineffective with inhibitors; B (Cryoprecipitate) contains human FVIII, neutralized; C (Recombinant Human Factor VIII) directly neutralized; E (High-dose Prednisone) addresses underlying autoimmunity but not acute hemostasis. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ISTH) recommending recombinant porcine FVIII or bypassing agents (rFVIIa/FEIBA) as first-line for bleeding in acquired hemophilia with inhibitors; vignette realistically depicts postpartum presentation. Minimal fix: No edit needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: 28-year-old G2P2 woman 3 months postpartum with ecchymoses and bleeding from minor cut; aPTT 78s (prolonged), PT 12s (normal); mixing study fails to correct aPTT; Factor VIII activity <1%. These indicate acquired hemophilia A due to postpartum anti-Factor VIII inhibitor, requiring bypassing therapy for acute bleeding control. Main logical issue(s): None; stem provides sufficient details for discrimination without contradictions or underspecification, supporting D as unique best (recombinant porcine Factor VIII has low cross-reactivity with human inhibitors). Alternatives inferior: A (Desmopressin) stimulates endogenous FVIII release, ineffective with inhibitors; B (Cryoprecipitate) contains human FVIII, neutralized; C (Recombinant Human Factor VIII) directly neutralized; E (High-dose Prednisone) addresses underlying autoimmunity but not acute hemostasis. Main medical accuracy issue(s): None; aligns with current guidelines (e.g., ISTH) recommending recombinant porcine FVIII or bypassing agents (rFVIIa/FEIBA) as first-line for bleeding in acquired hemophilia with inhibitors; vignette realistically depicts postpartum presentation. Minimal fix: No edit needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed126", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed126-010", "question": "A traveler returns from Malaysian Borneo with daily high-grade fevers and severe thrombocytopenia. Blood smear reveals high parasitemia with 'band form' trophozoites resembling Plasmodium malariae, but the clinical severity mimics Plasmodium falciparum. Which feature distinguishes the replication cycle of this pathogen from P. falciparum?", "options": ["Option A: 24-hour erythrocytic cycle", "Option B: 48-hour erythrocytic cycle", "Option C: 72-hour erythrocytic cycle", "Option D: Presence of a hypnozoite stage", "Option E: Preferential invasion of reticulocytes"], "answer": "A", "answer_index": 0, "explanation": "The pathogen is Plasmodium knowlesi, a zoonotic malaria. A key feature driving its potential for hyperparasitemia and severe disease is its unique 24-hour (quotidian) erythrocytic replication cycle. P. falciparum has a 48-hour cycle, and P. malariae has a 72-hour cycle. P. knowlesi does not have a hypnozoite stage (unlike P. vivax/ovale).", "generator_model": "gemini-3-pro-preview", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Traveler from Malaysian Borneo with daily high-grade fevers, severe thrombocytopenia, high parasitemia on blood smear showing 'band form' trophozoites resembling P. malariae but clinical severity mimicking P. falciparum—these drive identification of Plasmodium knowlesi as the pathogen, distinguished by its 24-hour erythrocytic cycle versus P. falciparum's 48-hour cycle.\\n\\nBest-answer defensibility: a) The question asks for the replication cycle feature distinguishing this pathogen (P. knowlesi) from P. falciparum. b) Discriminating findings: Malaysian Borneo origin (zoonotic reservoir), daily fevers (quotidian cycle), severe thrombocytopenia and hyperparasitemia (falciparum-like severity), band-form trophozoites (malariae mimic). c) Most likely: P. knowlesi infection. d) Keyed answer A (24-hour cycle) fits perfectly, as it explains rapid replication and severity without requiring assumptions. e) B (48-hour) describes P. falciparum, not distinguishing; C (72-hour) fits P. malariae; D (hypnozoite) is for P. vivax/ovale, absent in knowlesi; E (reticulocyte preference) is for P. vivax, while knowlesi invades mature RBCs.\\n\\nMain logical issues: None; stem supports unique best answer A without contradictions or underspecification. Main medical accuracy issues: None; aligns with current guidelines on P. knowlesi (e.g., WHO recognition of 24-hour cycle, zoonotic malaria in SE Asia). Minimal fix: None needed; item is unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues: Traveler from Malaysian Borneo with daily high-grade fevers, severe thrombocytopenia, high parasitemia on blood smear showing 'band form' trophozoites resembling P. malariae but clinical severity mimicking P. falciparum—these drive identification of Plasmodium knowlesi as the pathogen, distinguished by its 24-hour erythrocytic cycle versus P. falciparum's 48-hour cycle.\n\nBest-answer defensibility: a) The question asks for the replication cycle feature distinguishing this pathogen (P. knowlesi) from P. falciparum. b) Discriminating findings: Malaysian Borneo origin (zoonotic reservoir), daily fevers (quotidian cycle), severe thrombocytopenia and hyperparasitemia (falciparum-like severity), band-form trophozoites (malariae mimic). c) Most likely: P. knowlesi infection. d) Keyed answer A (24-hour cycle) fits perfectly, as it explains rapid replication and severity without requiring assumptions. e) B (48-hour) describes P. falciparum, not distinguishing; C (72-hour) fits P. malariae; D (hypnozoite) is for P. vivax/ovale, absent in knowlesi; E (reticulocyte preference) is for P. vivax, while knowlesi invades mature RBCs.\n\nMain logical issues: None; stem supports unique best answer A without contradictions or underspecification. Main medical accuracy issues: None; aligns with current guidelines on P. knowlesi (e.g., WHO recognition of 24-hour cycle, zoonotic malaria in SE Asia). Minimal fix: None needed; item is unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]